Alterity Therapeutics Limited (ATHE) Social Stream
Alterity Therapeutics Ltd (ATHE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Alterity Therapeutics Ltd.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Price Target Last Issued August 20, 2021
ATHE Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, Alterity Therapeutics Ltd's number of analysts covering the stock is higher than nearly none of them.
- In terms of how Alterity Therapeutics Ltd fares relative to all US stocks, note that its variance in analysts' estimates is lower than nearly 100% of that group.
- Alterity Therapeutics Ltd's average analyst price target is higher than 3.16% of Pharmaceutical Products stocks.
- Alterity Therapeutics Ltd's upside potential (average analyst target price relative to current price) is higher than 83.29% of stocks in the small market cap category.
In the Pharmaceutical Products industry, ASRT, ASMB, and ARQT are the three stocks most similar to Alterity Therapeutics Ltd regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding ATHE using the data that counts. Try POWR Ratings for free.